netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Alemtuzumab found 11 matches
Open monograph to display formulary status BNF Category
  Alemtuzumab  (Lemtrada®) Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Alemtuzumab  (MabCampath®) Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Anakinra  (Kineret®) Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Cytotoxic Drug Bendamustine Malignant disease and immunosuppression - Alkylating drugs - 08.01.01
  Rituximab Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)
link in drug section MHRA Drug Safety Update (Feb 2020): Lemtrada▼ (alemtuzumab): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions (08.02.03)
link in drug section MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)
link in drug section MHRA Drug Safety Update (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune- mediated adverse reactions: new restrictions to use and strengthened monitoring requirements (08.02.03)
link in drug section NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis  (08.02.03)
link in drug section NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis  (08.02.03)


 
netFormulary